This recent Ars Technica article showcases a textbook example of the perils of mixing profit with medicine. While the headline of the article is a bit dramatic, the underlying storyline is clear-cut: Pharmaceutical company makes expensive cancer drug (Imbruvica, generic name ibrutinib, at $133 per 140 mg pill, with a dosage of 140 mg to … Continue reading A cancer drug’s new side effect is a thinning wallet